Skip to main content
. 2018 Aug 17;15:56. doi: 10.1186/s12977-018-0440-3

Fig. 1.

Fig. 1

Growth of 5326 and 96USSN20 clinical isolates in escalating concentrations of dolutegravir (DTG), bictegravir (BIC), cabotegravir (CAB) and elvitegravir (EVG). The rise in drug concentrations were related to the acquisition of resistance mutations at the designated weeks of selection